Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioLexa in healthy subjects and mild to moderate atopic dermatitis
NCT04544943Phase 1Completed
- Sponsor
- Hoth Therapeutics
- Start
- May 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BioLexa in atopic dermatitis (AD) (7 arms), sponsored by Hoth Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 14 days. Started May 2021; status: completed.
02
Drugs
BioLexa
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04544943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544943.